Preclinical Success of IM-1021 in Reducing Tumor Growth, Revealed by Immunome

Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. 

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

The findings were showcased in a poster titled “Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload” during the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held in Barcelona on October 24, 2024. 

This poster detailed the preclinical performance of IM-1021 in both liquid and solid malignancies, emphasizing the improved ADME characteristics of HC74, which included:

- IM-1021 exhibited greater efficacy compared to zilovertamab vedotin in the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 model of triple-negative breast cancer. In the MDA-MB-468 experiment, 5 out of 8 subjects displayed complete responses after receiving three doses of 5 mg/kg.

- HC74 revealed enhanced potency (IC50=5nM) relative to deruxtecan (IC50=20nM) across a selection of 89 cancer cell lines.

- HC74 demonstrated quicker hepatocyte clearance, superior permeability, and reduced efflux compared to deruxtecan.

- When assessed in cell lines resistant to doxorubicin and vincristine, HC74 maintained its potency when compared to the parental NCI-H69 cell line.

“We believe that effective ADCs necessitate an optimal pairing of the target with the appropriate antibody, linker, and payload. In light of this data, we continue to view IM-1021 as a promising candidate in preclinical stages,” stated Dr. Jack Higgins, Chief Scientific Officer of Immunome. “The unique characteristics of HC74, particularly its strong activity in chemotherapy-resistant cell lines, open exciting avenues for clinical development. We are eager to file the IM-1021 IND and commence clinical trials following IND approval to further substantiate these results,” Dr. Higgins added.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of October 31, 2024, there are 95 investigational drugs for the ROR1 target, including 71 indications, 81 R&D institutions involved, with related clinical trials reaching 49, and as many as 10284 patents.

IM-1021 is a promising ADC drug being developed by Immunome, Inc. for the treatment of neoplasms, with a specific focus on targeting ROR1. While the drug is still in the early stages of development, its potential to provide a targeted therapeutic approach for a range of cancers makes it an exciting prospect in the field of biomedicine.